The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
The Visian ICL (Implantable Collamer Lens) is an exquisitely precise technology for the correction of high degrees of nearsightedness -- much higher than the reach of laser refractive surgery such as LASIK and PRK. Given the price of the ICL and the intraocular surgey required for its...
"He who pays the fiddler calls the tune." Here's an example of the fiddler pro-actively asking the guy in the room with the deepest pocket what he'd like to hear. If it's not something in the current repertoire, the fiddler seems willing to learn. However, by the time he's got...
The media reporting on the FDA hearings on LASIK has generally highlighted unhappy patients' stories and the comments of FDA officials and panel members. However, The Washington Post's Lauran Neergard has written an insightful article that foresees an important future trend in refractive surgery....
The market for eye drops for the treatment of open angle glaucoma is huge. Profit potential for pharmaceutical companies, however, is limited by the time period that they are afforded patent protection. Combigan, the just approved brimonidine/timolol combination therapy, affords Allergan new patent...
Presbyopia correcting IOLs currently represent 5% of all IOLs implanted in the United States (about 3.5 million per year). The products available in this category include the ReSTOR multifocal IOL (Alcon), the ReZoom multifocal IOL (AMO) and the cyrstalens accommodative IOL (eyeonics). Although...
Alacrity Biosciences has completed a Phase 2 clinical trial of ALTY-1501, an eye drop for the treatment of dry eye. Dry eye (or keratoconjunctivitis sicca (KCS) affects more than 10% of the US population and its incidence is increasing as baby boomers become senior citizens.
Although the small...
Genentech has had first year revenues of $800 million from its drug Lucentis, which is used intravitreaaly to treat macular degeneration on label and some other conditions off label. Although this amount of sales places Lucentis well within the blockbuster...
Rather than getting gobbled up by one of the big three players in Ophthalmology (B & L, Alcon and AMO), eyeonics is looking to go it alone into the public arena. The crystalens remains the only approved accommodative intraocular lens, but faces strong competition from the multifocals. ...
Alcon has suffered with its LADARVision system recalls and lawsuits, and has looked particularly troubled following AMO's acquisition of VISX. Although AMO/VISX remains the market leader for refractive correction, the Allegretto represents new technology with potential advantages in terms of accuracy...